Olaparib for recurrent triple-negative breast cancer with a specific gene change
Treatments studied
Part of Cancer clinical trials.
This study tests a drug called olaparib (a PARP inhibitor) in people with triple-negative breast cancer that has returned or spread, and whose tumors do not have a BRCA gene mutation but do have a change called BRCA1 promoter methylation. The goal is to see if olaparib can help shrink or slow the cancer, based on this specific tumor feature.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have triple-negative breast cancer that has come back or spread, and your tumor does not have a BRCA1/2 gene mutation but does have a specific change called BRCA1 promoter methylation.
- You have had no more than 2 prior treatments for the recurrent or metastatic stage.
- You have at least one tumor that can be measured on scans, and your overall health is good (ECOG score 0 or 1).
- You have not taken a PARP inhibitor (like olaparib) before, and you are not pregnant or breastfeeding.
- You have no known or suspected brain metastases, and you have not had another cancer in the past 5 years (except breast cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs — an immunotherapy (QL1706) and a PARP inhibitor (olaparib) — to see if it can help people with triple-negative breast cancer that has come back or spread, especially when their tumors have a specific DNA repair problem (HRD). It is for people who have already tried at least one prior treatment.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
This trial tests a chemotherapy drug (temozolomide) alone or combined with a targeted therapy (olaparib) for people with triple negative breast cancer. It may help if your tumor has a specific genetic marker (MGMT promoter methylation).
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
This trial tests an “at-the-source” medicine given before surgery to shrink triple-negative and/or BRCA-related breast cancer. It may help doctors see whether it improves tumor response and reduces cancer spread at surgery time.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.